Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors : should we treat beyond two years?
Source
Acta oncologica - ISSN 0284-186X-64 (2025) p. 979-988
Author(s)
Alexander Decruyenaere, Christine Gennigens, Sylvie Rottey, Annouschka Laenen, Emmanuel Seront, Els Everaert, Philip R. Debruyne, Heidi van den Bulck, Julie Bastin, Annelies Verbiest, Christof Vulsteke, Peter Schatteman, Daisy Luyten, Sandrine Aspeslagh, Nieves Martinez-Chanza, Marlies De Bock, Thomas Meyskens, Jolanda Verheezen, Barbara Brouwers, Benoit Beuselinck
Cookie consent
The University of Antwerp website uses cookies and similar technologies to ensure the basic functionality of the site and for statistical and optimisation purposes. It also uses cookies to display content such as YouTube videos and for marketing purposes. This last category consists of tracking cookies: these make it possible for your online behaviour to be tracked. You consent to this by clicking on Accept. Also read our Privacy statement